A detailed history of Goldman Sachs Group Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 418,867 shares of TERN stock, worth $2.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
418,867
Previous 698,714 40.05%
Holding current value
$2.45 Million
Previous $4.76 Million 26.59%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $1.82 Million - $3.02 Million
-279,847 Reduced 40.05%
418,867 $3.49 Million
Q2 2024

Aug 13, 2024

BUY
$4.54 - $8.2 $2.23 Million - $4.03 Million
491,728 Added 237.57%
698,714 $4.76 Million
Q1 2024

May 15, 2024

BUY
$4.86 - $8.19 $589,979 - $994,225
121,395 Added 141.83%
206,986 $1.36 Million
Q4 2023

Feb 13, 2024

SELL
$3.37 - $6.86 $585,385 - $1.19 Million
-173,705 Reduced 66.99%
85,591 $555,000
Q3 2023

May 14, 2024

BUY
$4.7 - $8.55 $816,413 - $1.49 Million
173,705 Added 202.95%
259,296 $1.3 Million
Q3 2023

Nov 14, 2023

BUY
$4.7 - $8.55 $947,115 - $1.72 Million
201,514 Added 348.75%
259,296 $1.3 Million
Q2 2023

May 14, 2024

SELL
$7.35 - $13.29 $231,686 - $418,927
-31,522 Reduced 35.3%
57,782 $505,000
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.29 $231,686 - $418,927
-31,522 Reduced 35.3%
57,782 $505,000
Q1 2023

May 14, 2024

BUY
$7.91 - $12.0 $620,729 - $941,688
78,474 Added 724.6%
89,304 $1.06 Million
Q1 2023

May 11, 2023

BUY
$7.91 - $12.0 $620,729 - $941,688
78,474 Added 724.6%
89,304 $1.06 Million
Q4 2022

May 14, 2024

SELL
$4.62 - $10.18 $5,017 - $11,055
-1,086 Reduced 9.11%
10,830 $110,000
Q4 2022

Feb 13, 2023

SELL
$4.62 - $10.18 $5,017 - $11,055
-1,086 Reduced 9.11%
10,830 $110,000
Q3 2022

May 14, 2024

SELL
$1.87 - $6.42 $8,736 - $29,994
-4,672 Reduced 28.16%
11,916 $70,000
Q3 2022

Nov 10, 2022

SELL
$1.87 - $6.42 $8,736 - $29,994
-4,672 Reduced 28.16%
11,916 $0
Q2 2022

May 14, 2024

SELL
$1.5 - $3.0 $103,504 - $207,009
-69,003 Reduced 80.62%
16,588 $41,000
Q2 2022

Aug 15, 2022

BUY
$1.5 - $3.0 $241 - $483
161 Added 0.98%
16,588 $41,000
Q1 2022

May 16, 2022

BUY
$2.83 - $6.7 $3,449 - $8,167
1,219 Added 8.02%
16,427 $49,000
Q4 2021

Feb 14, 2022

BUY
$5.65 - $10.73 $85,925 - $163,181
15,208 New
15,208 $108,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $220M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.